ResearcherActive in the last 2 years

Syvart Dennen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9872-4004; OpenAlex author ID A5028661589. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 2 papers

Papers 2

Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review. First author DOI 10.1080/14796694.2024.2435253 ↗
Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.36469/001c.142403 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Paul C. Cockrum · 2 shared papers, 2025 · strength 0.66
- Paper Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review. DOI 10.1080/14796694.2024.2435253 ↗
- Paper Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic P… DOI 10.36469/001c.142403 ↗
Ravi Paler · 1 shared paper, 2025 · strength 0.33
- Paper Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic P… DOI 10.36469/001c.142403 ↗
Ravi Kumar Paluri · 1 shared paper, 2025 · strength 0.33
- Paper Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review. DOI 10.1080/14796694.2024.2435253 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.